Toft Group Completes Executive Search for Greenwich Biosciences (NASDAQ: GWPH) in Carlsbad, CA


Executive search firm Toft Group has placed Mr. Jeff Krol as Vice President, Market Access at Greenwich Biosciences in Carlsbad, CA. Mr. Krol brings 25 years of experience in managed markets leadership. He most recently served with Avanir Pharmaceuticals as Executive Director, Managed Markets and Project Management, and previously served in the same company as Senior Director, Managed Markets. Mr. Krol earned his B.S. in Chemistry and Physics from The Ohio State University, and his M.S. in Education from the University of California, Berkeley.

About Greenwich Biosciences

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy.